University of Antwerp has described fibroblast activation protein (FAP) inhibitors reported to be useful for the diagnosis and treatment of cancer, disorders of coagulation, glucose metabolism and inflammatory disorders.
Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with diet-induced MASH.
